Resumen de: US2020057074A1

Antibodies are used as biomarkers to assist in distinguishing gluten immune reactivity and sensitivity, silent celiac disease, Crohn's disease and other gut-related pathologies from classical celiac disease. In one class of embodiments, sera, saliva or other samples from a human or other animal are tested for antibodies to (a) a wheat antigen; (b) a gliadin antigen; and (c) one or more of a wheat germ agglutinin, a gluteomorphin, a glutenin, a deamidated glutenin, a prodynorphin, and a dynorphin. Test results are considered particularly interesting where the wheat antigen and the gliadin antigen are both selected from the group consisting of native and deamidated forms of α-gliadin 33-mer, α-gliadin-17-mer, γ-gliadin-15-mer, ω-gliadin-17-mer, and glutenin 21-mer. Test plates and kits can advantageously test for antibodies to at least three, five, seven or all of mixed wheat antigens, α-gliadin, γ-gliadin, ω-gliadin, glutenin, α-glutenin, wheat germ agglutinin, gluteomorphin, prodynorphins, transglutaminase-2, transglutaminase-3, transglutaminase-6, and gliadin-bound transglutaminase.

Resumen de: US2020049708A1

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's GI tract, specifically the GI tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in GI tract samples, e.g. by nucleic acid analysis.

Resumen de: AU2020200423A1

DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

Resumen de: US2020038523A1

The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention. In addition, the present invention relates to a pharmaceutical or diagnostic composition; to the PSMA-specific binding protein of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the PSMA-specific binding protein produced by the method of the invention, for use in therapy and/or diagnosis, and in particular for use in the therapy and/or diagnosis of tumors, Crohn's disease and/or neurological diseases.

Resumen de: WO2018175913A1

Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.

Resumen de: US2020032264A1

Methods of treating IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CCL20, IL8, or TNFα levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CCL20, IL8, or TNFα levels are also disclosed. Also disclosed are methods of determining whether a subject with IBD is responsive or likely to be responsive to treatment an anti-SMAD7 therapy. Reduction of CCL20, IL8, or TNFα levels may correlated with IBD remission or decreases in CDAI score.

Resumen de: EP3598979A1

The invention provides a method and composition for ameliorating or reducing the symptoms, signs, and markers and for the treatment of irritable bowel syndrome, inflammatory bowel disease or gastritis in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition containing at least one probiotic microorganism strain comprising Pediococcus acidilactici for a time sufficient to ameliorate, reduce or treat at least one symptom, sign, or marker of irritable bowel syndrome, inflammatory bowel disease or gastritis.

Resumen de: US2020009210A1

The present invention relates to a pharmaceutical composition comprising an Indigo Pulverata Levis extract or a fraction thereof as an effective ingredient for preventing or treating inflammatory bowel disease. Exhibiting the effect of reducing the activity and expression of inflammatory activation markers and alleviating the disease activity index of inflammatory bowel disease, an Indigo Pulverata Levis extract or a fraction thereof according to the present invention may be useful as an agent for preventing and treating inflammatory bowel disease.

Resumen de: WO2020010254A1

Described are compositions and methods for treating inflammatory bowel diseases in a subject in need thereof. In certain aspects, the disclosure provides methods of treating a subject diagnosed with Irritable Bowel Disease (IBD), the method comprising administering to the subject an agent to reduce the number or pathogenic effects of a B. fragilis strain, wherein the subject is diagnosed with IBD by detecting the presence of the B. fragilis strain or a B. fragilis toxin in a biological sample of the patient.

Resumen de: US2020010895A1

A method for identifying a subject having at least an indication or predisposition for developing inflammatory bowel disease or colorectal cancer based upon the presence of Salmonella AvrA protein, nucleic acids and antibodies is provided as is a method for treating Salmonella infection-related colorectal cancer using a Wnt1 agonist.

Resumen de: EP3591398A1

The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.

Resumen de: WO2020004874A1

The present invention relates to a method for prognosing the occurrence and the causative factor of an inflammatory bowel disease such as ulcerative colitis and Crohn's disease by means of a metagenomic analysis of bacteria and bacteria-derived vesicles present in a human body-derived substance and, more particularly, to a method for diagnosing the causative factor and occurrence risk of an inflammatory bowel disease by analyzing a metagenomic sequence present in bacteria and bacteria-derived vesicles present in stool. Trillions of bacteria are present in the intestine, and vesicles are secreted outside the cells for exchange of information. Bacteria are not absorbed into the intestinal epithelial cells, but the vesicles secreted from the bacteria pass through the mucous, are absorbed into the intestinal epithelial cells and can increase or reduce inflammation. The present invention can be facilitated as a method for diagnosing the occurrence risk and causative factor of an inflammatory bowel disease by means of a gene metagenomic sequence analysis of bacteria and bacteria-derived vesicles present in a human body-derived substance. Also, the present invention enables early diagnosis even after an occurrence of an inflammatory bowel disease, reduces the occurrence of an inflammatory bowel disease, and can enhance therapeutic effects.

Resumen de: WO2020004874A1

The present invention relates to a method for prognosing the occurrence and the causative factor of an inflammatory bowel disease such as ulcerative colitis and Crohn's disease by means of a metagenomic analysis of bacteria and bacteria-derived vesicles present in a human body-derived substance and, more particularly, to a method for diagnosing the causative factor and occurrence risk of an inflammatory bowel disease by analyzing a metagenomic sequence present in bacteria and bacteria-derived vesicles present in stool. Trillions of bacteria are present in the intestine, and vesicles are secreted outside the cells for exchange of information. Bacteria are not absorbed into the intestinal epithelial cells, but the vesicles secreted from the bacteria pass through the mucous, are absorbed into the intestinal epithelial cells and can increase or reduce inflammation. The present invention can be facilitated as a method for diagnosing the occurrence risk and causative factor of an inflammatory bowel disease by means of a gene metagenomic sequence analysis of bacteria and bacteria-derived vesicles present in a human body-derived substance. Also, the present invention enables early diagnosis even after an occurrence of an inflammatory bowel disease, reduces the occurrence of an inflammatory bowel disease, and can enhance therapeutic effects.

Resumen de: US2019376948A1

A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.

Resumen de: US2019374496A1

This present invention relates to the use of eicosapentaenoic acid (EPA) for the treatment of ulcerative colitis (UC), and more particularly, the use of highly purified eicosapentaenoic acid as free fatty acids (EPA-FFA) having a purity of at least 95% for reducing inflammation in a subject suffering from ulcerative colitis and wherein the levels of IL-10 and SOCS3 are increased and the microbiome of the intestinal mucosal tissue is favorably modulated.

Resumen de: WO2019232468A1

Methods, kits, devices, and materials described herein provide blood-based diagnostic, prognostic, and treatment-monitoring biomarkers for IBS and IBD. These biomarkers can be used to distinguish IBS and/or IBD patients from healthy controls, for example, as well as to distinguish between IBS and IBD or other related disorders.

Resumen de: WO2019229247A1

The invention relates to a method comprising a step of determining the number, concentration and/or proportion of T lymphocytes with a CD4+ CD8ααlow phenotype and further expressing CCR6 and/or CXCR6, for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing a disease related to a decrease of F. prau. The invention also concerns the treatment of said disease by administering a population of these specific T lymphocytes. The Inventors have indeed identified two markers, CCR6 and CXCR6, enabling to select a population of F. prau-specific cells among CD4+ CD8ααlow T lymphocytes, from a blood sample and without needing to assess their F. prau specificity. T lymphocytes with a CD4+ CD8ααlow CCR6+ CXCR6+ phenotype are for example significantly decreased in IBD patients. The disease related to a decrease of F. prau is particularly an inflammatory bowel disease (IBD), such as Crohn's disease.

Resumen de: WO2019224663A1

The present invention refer to a diagnostic method based on mass spectrometry, in particular MALDI-TOF/MS, which carried out on a faecal sample previously collected from a subject, allows the diagnosis of an intestinal inflammatory disease. In particular, said method allows to obtain a peptidomic profile that permits diagnosing the presence of a chronic inflammatory bowel disease with high sensitivity and specificity. Said method allows to identify through a single analysis peptidomic profiles able to distinguish healthy persons from ill ones and among the ill ones to distinguish those affected by Crohn's disease of ulcerative rectocolitis.

Resumen de: JP2019196389A

To provide methods for identifying novel targets in treating and preventing metastasis, fibrosis and pain associated with wound healing.SOLUTION: Disclosed herein is the use of an inhibitor of CEP192 for treating fibrosis or scarring, or for producing drugs for inhibiting fibrosis or scarring, where the fibrosis is fibroma, pulmonary fibrosis, cystic fibrosis, hepatic cirrhosis, endomyocardial fibrosis due to a previous myocardial infarction, atrial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis of the lungs, a complication of pneumoconiosis, nephrogenic systemic fibrosis, Crohn's disease fibrosis, keloid fibrosis, scleroderma/systemic sclerosis of skin or lungs, arthrofibrosis or adhesive capsulitis fibrosis, and the scarring is skin scarring, cardiovascular scarring, cardiac tissue scarring, or neuronal scarring, and the inhibitor of CEP192 is an RNAi nucleic acid directed to CEP192.SELECTED DRAWING: None

Resumen de: US2019338283A1

The present invention relates to treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) using antisense nucleotides that are directed against polymorphic forms (e.g., those containing single nucleotide polymorphisms) of the SMAD7 mRNA. The invention thus relates to treatment methods for subjects having polymorphic forms of SMAD7 and antisense oligonucleotides that specifically target SMAD7 mRNA transcripts containing polymorphisms.

Resumen de: JP2019194600A

To provide a biomarker for IBS diagnosis.SOLUTION: The present invention provides a method for assisting diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD) and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.SELECTED DRAWING: Figure 5

Resumen de: WO2019212899A1

Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohns disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.

Resumen de: US2019341125A1

The present disclosure relates to a method of determining a risk of developing inflammatory bowel disease in a subject, the method comprising identifying whether at least 50 single nucleotide polymorphisms (SNPs) from Table A is present in a biological sample from the subject, wherein the presence of a risk allele of a SNP from Table A indicates that the subject has an increased risk of inflammatory bowel disease, and wherein the presence of an alternative allele indicates that the subject has a decreased risk of inflammatory bowel disease.

Resumen de: WO2019210203A1

Disclosed herein are methods, kits and compositions for treating a subject for an inflammatory bowel disease. These methods, kits and compositions may be particularly useful for subjects with single nucleotide polymorphisms in a G Protein-Coupled Receptor 35 (GPR35) encoding gene locus.

Resumen de: JP2019187416A

To identify a microorganism to cause the development of primary sclerosing cholangitis associated with ulcerative colitis.SOLUTION: The present invention provides Klebsiella pneumoniae strain that induces inflammation in the liver.SELECTED DRAWING: None